Lukasz Kuryk | Immunology and Microbiology | Research Excellence Award

Published on by Citation Awards

Lukasz Kuryk | Immunology and Microbiology | Research Excellence Award

National Institute of Public Health | Poland

Łukasz Kuryk, PhD, is a preclinical immuno-oncology researcher whose work centers on advancing next-generation oncolytic adenoviruses and innovative immune-based cancer therapies through rigorous translational development. With extensive expertise spanning preclinical drug development—including efficacy, safety, biodistribution, and mechanistic immunology—he has contributed significantly to the evolution of modern virotherapy and cancer immunotherapy platforms. As a Principal Investigator leading national and international research initiatives, he develops and evaluates novel viral and immune-modulating therapeutics with the goal of enhancing antitumor immunity and improving clinical outcomes. His career includes impactful roles at the National Institute of Public Health in Poland, where he has served as Associate Professor and Assistant Professor in the Department of Virology, driving research in immuno-oncology and cancer vaccine development. He has also contributed to pioneering studies at the Warsaw University of Technology within the Immuno-Oncology and Immunotherapy Laboratory, working at the interface of engineering, immunology, and infectious disease research. His international engagement includes work as a visiting researcher at the University of Padova, where he explored the use of EV-like nanoparticles as delivery platforms for oncolytic viruses, opening new avenues for therapeutic innovation. A co-inventor on multiple patents in oncolytic virotherapy and cancer vaccine technologies, he is recognized for fostering highly productive academic–industry collaborations that accelerate the translation of experimental therapeutics toward clinical relevance. He has authored more than fifty peer-reviewed publications that contribute to the expanding understanding of viral immunotherapies and tumor–immune interactions, establishing him as an influential scientist in the field. His career reflects a persistent commitment to advancing the scientific foundations and therapeutic potential of immuno-oncology through multidisciplinary collaboration, innovation, and translational impact.

Profile: Scopus | Orcid | Google Scholar

Featured Publications

Mathlouthi, S., Kuryk, L., Rinner, B., Bellio, G., Casagrande, L., Pesce, C., Fragassi, A., Salmaso, S., Mastrotto, F., & Garofalo, M. (2026). A 3D coculture model of hepatocellular carcinoma: Addressing challenges with glycopolymers re-targeted oncolytic viruses. Journal of Drug Delivery Science and Technology, 107658.

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Data 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Figures S1 to S7 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Methods 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Table 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Pankaj Kumar | Immunology and Microbiology | Best Researcher Award

Published on by Citation Awards

Pankaj Kumar | Immunology and Microbiology | Best 

Pankaj Kumar,The Ohio State University,United States

Pankaj Kumar is a Ph.D. researcher at Ohio State University. His research focuses on cancer biology, immunotherapy, and molecular mechanisms. He has published several papers and received awards for his work.

Publication Profile

orcid

Education

Pankaj Kumar completed his Ph.D. in Molecular and Cancer Biology from CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) Hyderabad, India (2014-2021). He received his M.S. in Biotechnology from Babasaheb Bhimrao Ambedkar University (BBAU), Lucknow, India (2011-2013) and B.S. in Biotechnology from Chhatrapati Shahu Ji Maharaj University (CSJMU), Kanpur, India (2008-2011).

Experience

Pankaj Kumar worked as a Postdoctoral Research Scholar at Ohio State University (February 2021-present). He was a Research Fellow (Ph.D.) at CSIR-Centre for Cellular and Molecular Biology, Hyderabad (August 2014-October 2021).

Awards And Honors

Pankaj Kumar received the Keystone Symposia travel award (2019), Carl Storm International Diversity (CSID) fellowship (2018), International Travel grant from ICMR-India (2018), CSIR-NET (Junior/Senior Research Fellowship-2015), and DBT-JRF (Junior Research Fellowship-2014).

Research Focus

Pankaj Kumar’s research focuses on cancer biology, immunotherapy, molecular mechanisms, and drug resistance. His work explores the molecular basis of cancer, multidrug resistance, tumor metastasis, and cancer immunotherapy.

Publications

  1. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation however independent of tumor progression 📄
  2. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis 📄
  3. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells 📄
  4. Targeting squalene epoxidase interrupts homologous recombination via the ER stress response and promotes radiotherapy efficacy 📄
  5. Heat shock transcription factor HSF2 modulates the autophagy response through the BTG2-SOD2 axis 📄
  6. Effect Of OSU-ERβ-12, A Carborane-based ERβ-selective Agonist, On Hepatic Fibrosis And NASH 📄
  7. The Battle of LPS Clearance in Host Defense vs. Inflammatory Signaling 📄